Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Etanercept, a biologic therapy, showed promise in improving rheumatoid arthritis (RA) symptoms in a prior phase II study.
• The study aimed to confirm the efficacy of longer-duration etanercept treatment with simplified dosing in RA patients.

Purpose of the Study:

• To evaluate the efficacy and safety of etanercept in patients with active rheumatoid arthritis.
• To assess the benefits of longer-term etanercept therapy and simplified dosing regimens.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 234 patients with active RA.
• Patients received twice-weekly subcutaneous injections of etanercept (10 or 25 mg) or placebo for six months.
• Disease activity was assessed using American College of Rheumatology (ACR) response criteria at 3 and 6 months.

Main Results:

• Etanercept significantly reduced RA disease activity in a dose-dependent manner.
• At 6 months, 59% of patients on 25 mg etanercept achieved a 20% ACR response versus 11% on placebo (P < 0.001).
• Significant improvements were observed in ACR 50% and 70% responses, joint counts, and quality of life for etanercept recipients.

Conclusions:

• Etanercept therapy is safe and provides rapid, significant, and sustained clinical benefits for patients with active rheumatoid arthritis.
• The drug was well-tolerated, with no dose-limiting toxicities observed during the study.